Clover Health announces that clover is one of the first cancer treatments to receive FDA approval
- by admin
CloverHealth, the leader in advanced cancer treatment, today announced that it has received FDA approval for the first stage of a phase III clinical trial of its Clover+Clover+Marmot (CC+M) platform.
Clover is the first product to undergo Phase III clinical trials in the U.S. The trial is the next step in our ongoing development and commercialization of Clover, the patented cancer treatment platform developed by our advanced-stage research and development team.
The CCR2-based drug is expected to provide the first clinical benefit for patients with advanced melanoma, a type of skin cancer that typically attacks the head and neck.
The first clinical trial will test the efficacy of CCR22 inhibitors in patients with metastatic melanoma in an effort to accelerate the development of new CCR21-based treatments.
“We are excited to continue the progress of our Clover program and look forward to being able to expand this new platform to patients who are already experiencing significant side effects from other advanced- stage cancer treatments,” said Dr. Joon Kim, president and CEO of Clovers research and clinical development.
“With the FDA approval, we look forward not only to further enhancing the Clover platform, but also to accelerate our development and launch of more novel, targeted therapies.”
The study will enroll patients in the Phase III trial, which will provide the initial data on the efficacy and safety of the drug in individuals with metastases.
Clovid-based treatment has shown promise for patients who suffer from advanced cancers such as advanced melanomas, but the development and clinical trials have been hindered by the high cost of clovid and the time it takes for patients to receive the drug.
Clovid is one part of a larger class of cancer therapies, called novel tumor suppressors, which includes inhibitors and vaccines.
The trial will enroll approximately 8,000 patients, with an estimated follow-up period of six to eight years.
About Clovud-related companiesClovud is a patented cancer therapy platform.
It has been approved for the treatment of metastatic, aggressive and non-small cell lung cancer.
It was first developed in 2010 by Dr. John D. Sallis, professor of pathology and biochemistry at the University of Pittsburgh School of Medicine and director of the Division of Oncology at the Heinz School of Pharmacy.
Clove, Clovod-related drugs are developed by the National Cancer Institute, the National Institutes of Health, and several of its research laboratories.
These companies are committed to developing and commercializing novel therapies and cancer-preventive technologies.
CloverHealth, the leader in advanced cancer treatment, today announced that it has received FDA approval for the first stage of…